“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...

Over-the-counter (OTC) inhalers are not approved for treating chronic obstructive pulmonary disease (COPD). Aside from the fact that they are ineffective for COPD, these inhalers can pose risks ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

The minimum strength you can get from a dermatologist is usually .025% tretinoin, which is a significantly stronger version of retinol than what is available OTC. Whatever you choose, just make sure ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Cipla's current price stands at Rs 1429.0, reflecting a 1.95% rise today, while its three-month returns have dipped by 4.53%. Cipla has achieved a positive price breakout and is trading above its ...

Stock market today: The domestic benchmark indices, Nifty 50 and Sensex, retraced their earlier gains on Monday, as worries over global trade kept investors cautious, while Reliance Industries, a ...

Over-the-counter (OTC) weight loss supplements have gained a lot of attraction from people hoping to lose extra weight without the need for a doctor’s prescription. OTC weight loss supplements ...

Cipla is currently valued at Rs 1406.05, experiencing a drop of 2.44% today, and has recorded a return of -4.51% in the past three months. Cipla is currently priced at Rs 1426.10, with a daily change ...

Please view our affiliate disclosure. Creating a strong brand identity is one of the most important aspects of a business. A well-designed logo is often the first impression a company makes on ...

Umang Vohra, Global CEO and MD of Cipla has warned the Indian pharmaceutical industry may have to gear up for the possibility of having distributive global manufacturing network in the next 5-10 ...